Table I.

Patient characteristics and clinical phenotypes following primary CMV infection in D+R-LTRs.

LTR	Age (y)	Gender	Primary Diagnosis	Immunosuppression at Primary CMV Onset	Primary CMV Onseta	Relapsing Viremia
23	50	M	Idiopathic Pulmonary Fibrosis	CSA 175/100, RAPA 11,Pred 51	108	-
24	31	F	Cystic Fibrosis	TAC 1.52, MMF 0.52,Pred 101	96	+
25	34	F	Primary Pulmonary Hypertension	TAC 42, MMF 0.52,Pred 101	129	-
28	33	F	Cystic Fibrosis	TAC 62, MMF 0.52,Pred 101	210	-
29	62	F	COPD	TAC 2.52, MMF 0.52,Pred 101	168	+
31	55	M	Cystic Fibrosis	TAC 32, AZA 501,Pred 51	248	-
33	51	F	Idiopathic Pulmonary Fibrosis	TAC 22, MMF 0.53,Pred 7.51	186	+
34	59	F	COPD	TAC 42, MMF 0.252,Pred 101	174	-
35	27	M	Cystic Fibrosis	TAC 12, MMF 0.52,Pred 7.51	219	-
36	49	F	Idiopathic Pulmonary Fibrosis	TAC 42, MMF 0.252,Pred 101	167	+
37	56	F	Obliterative Bronchiolitis	TAC 52, MMF 0.54,Pred 101	133	-
38	56	M	COPD	TAC 12, MMF 12,Pred 101	155	-
40	54	F	COPD	TAC 1.52, MMF 0.54,Pred 151	122	-
41	64	F	Bronchiectasis	TAC 42, MMF 0.52,Pred 51	184	-
43	51	M	Sarcoidosis	TAC 42, MMF 0.52,Pred 151	83	+
45	21	M	Cystic Fibrosis	TAC 2.52, MMF 0.53,Pred 151	92	-
46	59	M	COPD	TAC 1.52, MMF 12,Pred 201	37	+
48	47	M	Idiopathic Pulmonary Fibrosis	TAC 22, MMF 0.252,Pred 101	162	+
51	41	F	Pulmonary Hypertension	TAC 22, MMF 0.52,Pred 7.51	214	-
53	35	F	Cystic Fibrosis	TAC 22, MMF 0.52,Pred 101	125	+
56	61	F	COPD	TAC 12, MMF 0.52,Pred 101	142	+
57	56	M	Idiopathic Pulmonary Fibrosis	TAC 22, MMF 0.252,Pred 101	118	+
60	62	M	Idiopathic Pulmonary Fibrosis	TAC 42, MMF 0.252,Pred 101	410	-
Summaryc	48.4(12.5)	M 43.4 %			160.1 (73.7)	+ 43.4 %

^aDays post-transplant

^bViral load at time of sampling

^cValues represent mean or percent of indicated group (SD)

AZA, azathioprine (dose in milligrams); COPD, chronic obstructive pulmonary disease; CSA, cyclosporine (dose in milligrams); F, female; M, male; MMF, mycophenolate mofetil (dose in grams); Pred, prednisone (dose in milligrams); TAC, tacrolimus (dose in milligrams with superscript times per day).